Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11903287 | 1.00 | KMT2A (0.57) | KMT2ASMN1; SMN2ALDH1A1GAAL3MBTL1 | |
| SCHEMBL8476179 | 1.00 | KMT2A (0.57) | KMT2ASMN1; SMN2ALDH1A1GAAL3MBTL1 | |
| SCHEMBL1815681 | 0.89 | PTGS2 (0.50) | KMT2ASMN1; SMN2ALDH1A1GAAL3MBTL1 | |
| SCHEMBL9539620 | 0.83 | ALDH1A1 (0.54) | KMT2ASMN1; SMN2ALDH1A1GAAL3MBTL1 | |
| SCHEMBL155984 | 0.83 | ALDH1A1 (0.54) | KMT2ASMN1; SMN2ALDH1A1GAAL3MBTL1 | |
| SCHEMBL103235 | 0.83 | ALDH1A1 (0.54) | KMT2ASMN1; SMN2ALDH1A1GAAL3MBTL1 | |
| SCHEMBL104518 | 0.83 | ALDH1A1 (0.54) | KMT2ASMN1; SMN2ALDH1A1GAAL3MBTL1 | |
| SCHEMBL5009753 | 0.82 | KMT2A (0.49) | KMT2ASMN1; SMN2ALDH1A1GAAL3MBTL1 | |
| Quinoline SCHEMBL27388890 | 0.82 | ALDH1A1 (0.47) | KMT2ASMN1; SMN2ALDH1A1GAAL3MBTL1 | |
| SCHEMBL4280687 | 0.82 | ESR1 (0.42) | KMT2ASMN1; SMN2LMNACYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108349967-B | 1,3, 4-thiadiazole compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2022-02-15 | — | — | CN | claimed |
| EP-2983473-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS Mountain Llc (US) | 2016-02-17 | — | — | EP | claimed |
| WO-2014144130-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC (US) | 2014-09-18 | — | — | WO | claimed |
| EP-1962830-B1 | AZAINDOLE INHIBITORS OF AURORA KINASES | GLAXOSMITHKLINE LLC (US) | 2013-03-27 | — | — | EP | claimed |
| US-7563910-B2 | Heterocyclic cannabinoid receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-07-21 | — | — | US | claimed |
| EP-1749002-B1 | PYRROLE OR IMIDAZOLE AMIDES FOR TREATING OBESITY | HOFFMANN LA ROCHE (CH) | 2009-05-27 | — | — | EP | claimed |
| US-7495102-B2 | Azaindole inhibitors of aurora kinases | SMITHKLINE BEECHAM CORPORATION (US) | 2009-02-24 | — | — | US | claimed |
| EP-1962830-A2 | AZAINDOLE INHIBITORS OF AURORA KINASES | SmithKline Beecham Corporation (US) | 2008-09-03 | — | — | EP | claimed |
| US-20080081808-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | SMITHKLINE BEECHAM CORPORATION | 2008-04-03 | — | — | US | claimed |
| WO-2007076348-A2 | AZAINDOLE INHIBITORS OF AURORA KINASES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-05 | — | — | WO | claimed |
| EP-1749002-A1 | PYRROLE OR IMIDAZOLE AMIDES FOR TREATING OBESITY | F.HOFFMANN-LA ROCHE AG (CH) | 2007-02-07 | — | — | EP | claimed |
| WO-2005108393-A1 | PYRROLE OR IMIDAZOLE AMIDES FOR TREATING OBESITY | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-17 | — | — | WO | claimed |
| US-20050250769-A1 | Heterocyclic cannabinoid receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-10 | — | — | US | claimed |
| WO-2003027064-A1 | SIMPLIFIED RESINIFERATOXIN ANALOGUES AS VANILLOID RECEPTOR AGONIST SHOWING EXCELLENT ANALGESIC ACTIVITY AND THE PHARMACEUTICAL CO MPOSITIONS CONTAINING THE SAME | DIGITAL BIOTECH CO. LTD,. (KR) | 2003-04-03 | — | — | WO | claimed |
| WO-1997023508-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1997-07-03 | — | — | WO | claimed |
| CN-119264128-A | Thiadiazole and pyridazine parent nucleus compound, preparation method and pharmaceutical application thereof | 中国医学科学院药物研究所 | 2025-01-07 | — | — | CN | disclosed |
| CN-115785465-B | Multi-responsiveness polarized light pigment particle and preparation method and application thereof | 现代纺织技术创新中心(鉴湖实验室) | 2023-08-18 | — | — | CN | disclosed |
| EP-0206609-A1 | Compounds and compositions having anti-inflammatory and analgesic activity | THE PROCTER & GAMBLE COMPANY (US) | 1986-12-30 | — | — | EP | disclosed |
| EP-0064964-B1 | THERAPEUTICALLY USEFUL 1-ALKYL-2-AMINOTETRALIN DERIVATIVES | Astra Läkemedel Aktiebolag (SE) | 1984-08-08 | — | — | EP | disclosed |
| EP-0041488-A1 | Therapeutically useful tetralin derivatives | Arvidsson, Folke Lars-Erik (SE) | 1981-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081808-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | AURKA, AURKC, AURKB | KMT2A 105/4885SMN1; SMN2 3558/4885ALDH1A1 1793/4885 |
| US-20050250769-A1 | Heterocyclic cannabinoid receptor antagonists | CNR1, CNR2, GPR18 | KMT2A 3110/4885SMN1; SMN2 3964/4885ALDH1A1 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.